村井 弘之 むらい ひろゆき 先生

来歴等

略歴

1988年 九州大学医学部 卒業
1990年 広島赤十字・原爆病院 医師
1991年 九州大学病院 医員
1995年 Roswell Park Cancer Institute 研究員
1998年 九州厚生年金病院 神経内科 医長
2000年 九州大学病院 神経内科 助手
2005年 九州大学病院 神経内科 講師
2007年 飯塚病院 神経内科 部長、脳卒中センター長
2012年 九州大学大学院医学研究院 神経内科学 准教授
2015年 九州大学大学院医学研究院 脳神経治療学 教授
2017年 国際医療福祉大学医学部 脳神経内科学 主任教授

論文

• 1. International consensus guidance for management of myasthenia gravis. Neurology 87: 419-425, 2016

  Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I, Kuntz N, Massey JM, Melms A, Murai H, Nicolle MW, Palace J, Richman DP, Verschuuren J, Narayanaswami P:Executive summary

• 2. An international clinimetric evaluation of the MG-QOL15, resulting in slight revision and subsequent validation of the MG-QOL15r Muscle Nerve 54: 1015-1022, 2016

  Burns TM, Sadjadi R, Utsugisawa K, Gwathmey KG, Joshi A, Jones S, Bril V, Barnett C, Guptill JT, Sanders DB, Hobson-Webb L, Juel VC, Massey J, Gable KL, Silvestri NJ, Wolfe G, Cutter G, Nagane Y, Murai H, Masuda M,Farrugia ME, Carmichael C, Birnbaum S, Hogrel J-Y, Nafissi S, Fatehi F, Ou C, Liu W, Conaway M

• 3. Response to treatment of myasthenia gravis according to clinical subtype. BMC Neurol 16: 225, 2016

  Akaishi T, Suzuki Y, Imai T, Tsuda E, Minami N, Nagane Y, Uzawa A, Kawaguchi N, Masuda M, Konno S, Suzuki H, Murai H, Aoki M, Utsugisawa K

• 4. Early fast-acting treatment strategy against generalized myasthenia gravis. Muscle Nerve 55: 794-801, 2017

  Utsugisawa K, Nagane Y, Akaishi T, Suzuki Y, Imai T, Tsuda E, Minami N, Uzawa A, Kawaguchi N, Masuda M, Konno S, Suzuki H, Murai H, Aoki M

• 5. Social disadvantages associated with myasthenia gravis and its treatment: A multicenter cross-sectional study. BMJ Open 7: e013278, 2017

  Nagane Y, Murai H, Imai T, Yamamoto D, Tsuda E, Minami N, Suzuki Y, Uzawa A, Kawaguchi N, Masuda M, Konno S, Suzuki H, Aoki M, Utsugisawa K

• 6. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3,randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol 2017; 16(12):976-986.

  Howard JF, Jr, Utsugisawa K, Benatar M, Murai H, Barohn, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Muppidi S, Nowak RJ, O’Brien F, Wang JJ, Mantegazza R, and the REGAIN Study Group

• 7. Oral corticosteroid dosing regimen and long-term prognosis in generalized myasthenia gravis: a multicenter cross-sectional study in Japan. J Neurol Neurosurg Psychiatry 2018; 89(5):513-517.

  Imai T, Utsugisawa K, Murai H, Tsuda E, Nagane Y, Suzuki Y, Minami N, Uzawa A, Kawaguchi N, Masuda M, Konno S, Suzuki H, Akaishi T, Aoki M

• 8. Significance of follow-up thoracic imaging in myasthenia gravis. Clin Exp Neuroimmunol 2018; 9(4): 246-250

  Murai H, Nagane Y, Suzuki S, Imai T, Motomura M, Utsugisawa K

• 9. Long-term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle Nerve 2019; 60(1):14-24.

  Muppidi S, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Nowak RJ, Andersen H, Casasnovas C, De Bleecker JL, Vu TH, Mantegazza R, O’Brien FL, Wang JJ, Fujita KP, Howard JF

• 10. Clinical burden and healthcare resource utilization associated with myasthenia gravis: assessments from a Japanese claims database. Clin Exp Neuroimmunol 2019; 10(1): 61-68

  Murai H, Hasebe M, Murata A, Utsugisawa K

• 11. Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study. J Neurol Sci 2019; 407:116419.

  Murai H, Uzawa A, Suzuki Y, Imai T, Shiraishi H, Suzuki H, Okumura M, O’Brien F, Wang JJ, Fujita KP, Utsugisawa K

• 12. Suitable indications of eculizumab for patients with refractory generalized myasthenia gravis. Ther Adv Neurol Disord 2020; 13:1756286420904207.

  Oyama M, Okada K, Masuda M, Shimizu Y, Yokoyama K, Uzawa A, Kawaguchi N, Ikeguchi R, Hoshino Y, Hatano T, Ozawa Y, Nakahara J, Aizawa H, Kitagawa K, Hattori N, Kuwabara S, Murai H, Suzuki S

• 13. Response to eculizumab in patients with myasthenia gravis recently treated with chronic IVIg: a subgroup analysis of REGAIN and its open-label extension study. Ther Adv Neurol Disord 2020; 13: 1-8.

  Jacob S, Murai H, Utsugisawa K, Nowak RJ, Wiendl H, Fujita KP, O’Brien F, Howard JF

• 14. International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update Neurology 2021; 96(3): 114-122.

  Narayanaswami P, Sanders DB, Wolfe GI, Benatar M, Cea G, Evoli A, Gilhus NE, Illa I, Kuntz N, Massey JM, Melms A, Murai H, Nicolle M, Palace J, Richman DP, Verschuuren J.

• 15. Safety and effectiveness of eculizumab in Japanese patients with generalized myasthenia gravis: Interim analysis of post-marketing surveillance. Ther Adv Neurol Disord 2021; 14: 1-13.

  Murai H, Suzuki S, Hasebe M, Fukamizu Y, Rodrigues E, Utsugisawa K.

• 16. Zilucoplan: an investigational complement C5 inhibitor for the treatment of acetylcholine receptor autoantibody-positive generalized myasthenia gravis. Expert Opin Investig Drugs 2021; 30: 483-493.

  Howard JF, Vissing J, Gilhus NE, Leite MI, Utsugisawa K, Duda PW, Farzaneh-Far R, Murai H, Wiendl H

• 17. Safety, and Tolerability of Efgartigimod in Patients with Generalized Myasthenia Gravis (gMG): Analysis of the Randomized Phase 3 ADAPT Study. Lancet Neurol 2021; 20(7): 526-536　

  Howard JF, Bril V, Vu T, Karam C, Peric S, Margania T, Murai H, Bilinska M, Shakarishvili R, Smilowski M, Guglietta A, Ulrichts P, Vangeneugden T, Utsugisawa K, Verschuuren J, Mantegazza R, ADAPT Investigator Study Group: Efficacy,

• 18. The patient-reported impact of myasthenia gravis in the real world: protocol for a digital observational study (MyRealWorld MG). BMJ Open 2021; 11(7): e048198　

  Berrih-Aknin S, Claeys KG, Law N, Mantegazza R, Murai H, Saccà F, Dewilde S, Janssen MF, Bagshaw E, Kousoulakou H, Larkin M, Beauchamp J, Leighton T, Paci S

• 19. Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders. Lancet Neurol 2022; 21(2): 189-202.

  Verschuuren J, Palace J, Murai H, Tannemaat M, Kaminski H, Bril V.

• 20. Safety and effectiveness of eculizumab in Japanese patients with generalized myasthenia gravis: Analysis of 1-year postmarketing surveillance. Clin Exp Neuroimmunol 2022; 13(4): 280-289

  Murai H, Suzuki S, Fukamizu Y, Osawa T, Kikui H, Utsugisawa K

• 21. Nationwide survey of Lambert-Eaton myasthenic syndrome in Japan. BMJ Neurol Open 2022; 4(2): e000291.

  Yoshikawa H, Adachi Y, Nakamura Y, Kuriyama N, Murai H, Nomura Y, Sakai Y, Iwasa K, Furukawa Y, Kuwabara S, Matsui M

• 22. Two-step nationwide epidemiological survey of myasthenia gravis in Japan 2018. PLoS One 2022; 17: e0274161.

  Yoshikawa H, Adachi Y, Nakamura Y, Kuriyama N, Murai H, Nomura Y, Sakai Y, Iwasa K, Furukawa Y, Kuwabara S, Matsui M

• 23. Efgartigimod for generalized myasthenia gravis with or without anti-acetylcholine receptor antibodies: a worldwide and Japanese perspective. Exp Rev Clin Immunol 2022; 18(12): 1207-1215

  Suzuki S, Uzawa A, Murai H

• 24. Patient-reported burden of myasthenia gravis: baseline results of the international prospective, observational, longitudinal real-world digital study MyRealWorld-MG. BMJ open 2023; 13(1): e066445.

  Dewilde S, Philips G, Paci S, Beauchamp J, Chiroli S, Quinn C, Day L, Larkin M, Palace J, Berrih-Aknin S, Claeys KG, Muppidi S, Mantegazza R, Saccà F, Meisel A, Bassez G, Murai H, Janssen M.

• 25. Japan MG registry: Chronological surveys over 10 years. Clin Exp Neuroimmunol 2023; 14(1): 5-12.

  Suzuki S, Masuda M, Uzawa A, Nagane Y, Konno S, Suzuki Y, Kubota T, Sugimoto T, Samukawa M, Watanabe G, Ishizuchi K, Akamine H, Onishi Y, Yoshizumi K, Uchi T, Amino I, Ueta Y, Minami N, Kawaguchi N, Kimura T, Takahashi M, Murai H, Utsugisawa K.

• 26. The Japanese clinical guidelines 2022 for myasthenia gravis and Lambert–Eaton myasthenic syndrome. Clin Exp Neuroimmunol 2023; 14(1): 19-27.

  Murai H, Utsugisawa K, Motomura M, Imai T, Uzawa A, Suzuki S.

著書

• 1. 村井弘之：重症筋無力症 私の治療2019-20年度版 猿田享男、北村惣一郎（監修），日本医事新報社 2019

• 2. 村井弘之：脳神経内科診断ハンドブック—重症筋無力症, LEMS 下畑享良（編著）, 中外医学社 2021

• 3. 村井弘之：今日の治療指針—神経筋疾患の血漿浄化療法 福井次矢, 高木 誠, 小室一成 (編集) 医学書院 2022

• 4. 村井弘之：朝倉内科学第12版 神経筋接合部疾患 矢崎義雄、小室一成（総編集）、朝倉書店 2022

• 5. 村井弘之：COVID-19神経ハンドブック —急性期，後遺症からワクチン副反応まで—COVID-19と神経筋接合部疾患 下畑享良（編著）, 中外医学社 2022

受賞

• 1. 黒岩後藤賞 （2005年7月）

• 2. 九州大学神経内科奨励賞 （1993年7月）

その他

• 【テレビ出演】

• 1. テレビ朝日：名医とつながる！たけしの家庭の医学「身体のだるさ」2018年5月15日